Edesa Biotech Management
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Par Nijhawan (51 yo)
Dr. Pardeep Nijhawan, also known as Par, M.D., FRCPC, AGAF serves as Chief Executive Officer, Company secretary and Director at Edesa Biotech, Inc. since June 7, 2019 and having previously founded and led...
CEO Compensation Analysis
|Par Nijhawan's Compensation vs Edesa Biotech Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||US$1m||US$315k|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||US$411k||US$300k|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||US$165k||US$105k|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$61k||US$27k|
Compensation vs Market: Par's total compensation ($USD1.32M) is above average for companies of similar size in the US market ($USD787.63K).
Compensation vs Earnings: Par's compensation has increased whilst the company is unprofitable.
Experienced Management: EDSA's management team is considered experienced (3.3 years average tenure).
Experienced Board: EDSA's board of directors are considered experienced (3.3 years average tenure).